PolyPid Ltd. Logo

PolyPid Ltd.

Develops localized, prolonged-release drug therapies for surgery, oncology & metabolic diseases.

PYPD | US

Overview

Corporate Details

ISIN(s):
IL0011326795
LEI:
Country:
United States of America
Address:
18 HASIVIM STREET, 4959376 PETACH TIKVA
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

PolyPid Ltd. is a late-stage biopharmaceutical company focused on developing and commercializing locally administered therapies to improve surgical outcomes. The company's proprietary PLEX™ (Polymer-Lipid Encapsulation) technology is a drug delivery platform designed for the localized, controlled, and prolonged release of therapeutic agents. Its lead product candidate, D-PLEX₁₀₀, is in advanced clinical development for the prevention of surgical site infections (SSIs) following abdominal colorectal surgery. PolyPid is also leveraging its PLEX platform to expand its pipeline into other high-value markets, including oncology and metabolic diseases, with a long-acting GLP-1 receptor agonist delivery system for the diabetes and weight loss market.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all PolyPid Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for PolyPid Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for PolyPid Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
GemVax & KAEL Co.,Ltd. Logo
Makes contamination controls for semiconductors & develops Alzheimer's therapeutics.
South Korea 082270
Gencurix Inc. Logo
Develops molecular diagnostic tests for cancer detection, prognosis, and treatment selection.
South Korea 229000
GENELUX Corp Logo
Developing oncolytic viral immunotherapies for difficult-to-treat cancers using a vaccinia virus.
United States of America GNLX
GENEMATRIX INC. Logo
Develops multiplex PCR diagnostics and new drugs for infectious diseases like HPV and tuberculosis.
South Korea 109820
Genenta Science S.p.A. Logo
Develops cell & gene therapies using engineered stem cells to treat solid tumors.
United States of America GNTA
GeneOne Life Science, Inc. Logo
Develops nucleic acid vaccines & therapies for infectious diseases, cancer & autoimmune disorders.
South Korea 011000
Generation Bio Co. Logo
Developing siRNA genetic medicines via targeted nanoparticles for autoimmune diseases.
United States of America GBIO
Genetic Analysis AS Logo
Develops microbiome diagnostics to detect gut dysbiosis for clinical and pharma partners.
Norway GEAN
GENFIT Logo
Biopharma developing therapies & diagnostics for rare, life-threatening liver diseases.
France GNFT
Genfit S.A. Logo
Biopharma developing therapeutics and diagnostics for rare and life-threatening liver diseases.
United States of America GNFT

Talk to a Data Expert

Have a question? We'll get back to you promptly.